FDA Drug Development Tool (DDT) Qualification

About Echosens

Echosens is a pioneer and global leader in non-invasive liver diagnostics, with its FibroScan® technology established as the clinical gold standard for assessing liver fibrosis and steatosis. The company has a vast installed base of over 6,500 devices in more than 127 countries, supported by extensive clinical validation including over 6,270 peer-reviewed publications and inclusion in 250+ international guidelines. Echosens is expanding its platform from a diagnostic device into a broader liver health management ecosystem through cloud-based data solutions, integrated biomarker scores, and targeted initiatives in pharmaceutical partnerships and direct-to-patient awareness.

Therapeutic Areas